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Objective To determine safety and pharmacodynamics/efficacy of
teduglutide in children with intestinal failure associated with short bowel
syndrome (SBS-IF).
Study design This 12-week, open-label study enrolled patients aged
1-17 years with SBS-IF who required parenteral nutrition (PN) and showed
minimal or no advance in enteral nutrition (EN) feeds. Patients enrolled
sequentially into 3 teduglutide cohorts (0.0125 mg/kg/d [n = 8], 0.025 mg/
kg/d [n = 14], 0.05 mg/kg/d [n = 15]) or received standard of care (SOC,
n = 5). Descriptive summary statistics were used.
Results All patients experienced ≥1 treatment-emergent adverse event;
most were mild or moderate. No serious teduglutide-related treatment-
emergent adverse events occurred. Between baseline and week 12, pre-
scribed PN volume and calories (kcal/kg/d) changed by a median of −41%
and −45%, respectively, with 0.025 mg/kg/d teduglutide and by −25% and
−52% with 0.05 mg/kg/d teduglutide. In contrast, PN volume and calo-
ries changed by 0% and −6%, respectively, with 0.0125 mg/kg/d teduglutide
and by 0% and −1% with SOC. Per patient diary data, EN volume in-
creased by a median of 22%, 32%, and 40% in the 0.0125, 0.025, and
0.05 mg/kg/d cohorts, respectively, and by 11% with SOC. Four patients
achieved independence from PN, 3 in the 0.05 mg/kg/d cohort and 1 in
the 0.025 mg/kg/d cohort. Study limitations included its short-term, open-
label design, and small sample size.
Conclusions Teduglutide was well tolerated in pediatric patients with
SBS-IF. Teduglutide 0.025 or 0.05 mg/kg/d was associated with trends toward
reductions in PN requirements and advancements in EN feeding in chil-
dren with SBS-IF. (J Pediatr 2017;181:102-11).
Trial registration ClinicalTrials.gov: NCT01952080; EudraCT:
2013-004588-30.
AE Adverse event
EN Enteral nutrition
GI Gastrointestinal
GLP Glucagon-like peptide
IF Intestinal failure
ITT Intent-to-treat
PD Pharmacodynamics
PN Parenteral nutrition
SBS Short bowel syndrome
SBS-IF Intestinal failure associated with short bowel syndrome
SOC Standard of care
TEAE Treatment-emergent adverse event
TESAE Treatment-emergent serious adverse event
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Pediatric short bowel syndrome (SBS) is a malabsorptivecondition usually caused by surgical intestinal resec-tion due to congenital abnormalities, vascular insuf-
ficiency, or severe inflammatory intestinal disease.1 The
incidence in childhood varies between 0.02% and 1.2% of live
births.1-3 Although parenteral nutrition (PN) can be a life-
saving therapy, long-term dependence on PN is associated with
severe, possibly life-threatening complications, including
catheter-related bloodstream infections, loss of central venous
access, liver disease, and metabolic bone disease,4-6 resulting
in impaired quality of life.7 With advances in the manage-
ment of intestinal failure (IF) in pediatric patients and the in-
stitution of interdisciplinary teams, up to 85% of infants with
IF achieve PN independence within 1-3 years with aggressive
attempts at enteral feeding8-11; however, older pediatric pa-
tients with intestinal failure associated with short bowel syn-
drome (SBS-IF) who do not experience sufficient intestinal
adaptation to achieve enteral autonomy under the current stan-
dard of care (SOC) are less likely to experience further intes-
tinal adaptation sufficient to permit advancements in oral/
enteral feeds or reductions in PN.11,12 Additional strategies and
therapies that promote intestinal adaptation in these pa-
tients are needed for both the subset of infants that fails to adapt
within the first year and the older pediatric patients who remain
dependent on PN.
Glucagon-like peptide (GLP)-2 is an intestinotrophic
hormone that acts by increasing crypt epithelial prolifera-
tion, reducing epithelial apoptosis, enhancing visceral blood
flow, amplifying nutrient absorption, and slowing intestinal
motility.13 Teduglutide, a GLP-2 analogue with resistance to in
vivo degradation, expands the absorptive intestinal epithe-
lium by significantly increasing villus height in adult patients
with SBS.14-16 This article reports the results of a 12-week, open-
label, dose-finding study that assessed the short-term safety
and pharmacodynamics (PD)/efficacy of teduglutide com-
pared with SOC in pediatric patients (aged 1-17 years) with
SBS who were dependent on PN for >1 year.
Methods
We performed a 12-week, open-label, multicenter, phase 3
study at 17 sites in the US and the United Kingdom
(ClinicalTrials.gov: NCT01952080; EudraCT: 2013-004588-
30). The centers featured intestinal rehabilitation programs with
multidisciplinary clinical teams experienced in the care of pe-
diatric patients with SBS-IF.
After approval from local institutional review boards and
medical ethics committees, centers screened patients aged 1-17
years who had a ≥12-month history of SBS and dependence
on PN (defined as PN and/or intravenous fluids) for at least
30% of caloric and/or fluid/electrolyte needs. PN needs were
required to be stable at baseline, without any clinically mean-
ingful or substantial reduction in PN or advancement in enteral
nutrition (EN; oral and/or tube feeding) for ≥3 months. Key
exclusion criteria included body weight below the fifth per-
centile for age or <10 kg; gastrointestinal (GI) obstruction
within 6 months of screening; any major GI surgical inter-
vention within 3 months of screening; history of cancer or clini-
cally significant lymphoproliferative disease (excluding in situ
nonaggressive and surgically resected cancer); active Crohn’s
disease treated with biologic therapy within 6 months of screen-
ing or active inflammatory bowel disease treated with immu-
nosuppressant therapy; evidence of pseudo-obstruction or
dysmotility syndrome; use of native GLP-2, GLP-1, or human
growth hormone within 3 months before screening, or any pre-
vious use of teduglutide; and >3 SBS- or PN-related hospital
admissions within 3 months or any unscheduled hospital ad-
mission within 1 month before screening.
Patients were enrolled in 3 temporally staggered escalating
dose cohorts that received respective subcutaneous teduglutide
doses of 0.0125 mg/kg/d, 0.025 mg/kg/d, and 0.05 mg/kg/d
(Figure 1). The selection of doses was based on population
pharmacokinetic modeling and simulation data that sug-
gested that pediatric patients >1 year of age are likely to require
the same dosage used in adults (ie, 0.05 mg/kg/d).17 Patient
compliance with teduglutide dosing was verified during the
study by questioning patients or guardians regarding drug ad-
ministration and by accounting for empty medication vials col-
lected during scheduled study visits. In addition to the 3 dosing
cohorts, a fourth observational cohort received SOC. A data
safety monitoring board evaluated the safety and tolerability
for each sequential dosing cohort at week 4. The data safety
monitoring board review established that there were no un-
expected safety signals in ≥6 patients before the next cohort
proceeded. All patients were screened for ≥2 weeks before the
start of treatment to establish baseline characteristics and safety,
eligibility, and nutritional support variables.
After screening, study visits occurred weekly for the first 4
weeks and then every 2 weeks through the end of treatment
(weeks 5-12; Figure 1). To further monitor safety, patients were
contacted by telephone at the end of weeks 5, 7, 9, and 11. A
final study visit occurred at week 16 (4 weeks after treatment
finished). During the study period, patients or their guard-
ians maintained daily diaries to record EN intake. Decisions
regarding changes to nutritional and fluid intake were left to
the discretion of the primary treating physician, but the study
protocol provided guidelines for PN modifications (Table I;
available at www.jpeds.com).
Data Endpoints and Statistical Analyses
Data collected at every study visit included serum electro-
lytes, liver and pancreatic enzymes, albumin, blood urea ni-
trogen, creatinine, and weight and height measurements.
Treatment-emergent adverse events (TEAEs) and treatment-
emergent serious adverse events (TESAEs) were recorded.
Samples for teduglutide-specific antibody analysis were drawn
at baseline, final treatment visit (≥14 hours after the last dose),
and 4 weeks after treatment was completed. Teduglutide-
specific antibodies could be non-neutralizing antibodies (ie,
those that bind to teduglutide without affecting biological ac-
tivity) or neutralizing antibodies (ie, those that reduce drug
activity). The following PD/efficacy endpoints were used: change
in PN requirements, including the number of patients that
achieved complete PN independence; change in EN tolerance;
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and changes in plasma citrulline. PN volume, PN calorie, and
EN calorie endpoints were calculated based on provider pre-
scriptions. Changes in hours per day of PN infusion and enteral
feeding volumes were based on patient diary data, which were
considered more accurate measures of actual patient infu-
sion time and EN consumption than prescribed data. Fami-
lies were directed to follow prescriptions as closely as possible.
Rare changes in patient diaries were made because of techni-
cal impediments (eg, pump failure) or caregiver need. EN
calorie and volume data were based on formula-based liquid
nutrition received orally or via tube feeding only. Other solid
foods and liquids were considered ad lib nutrition and were
not included in the calculation of EN calories and volume.
Because of the small pool of eligible patients, the study analy-
sis was descriptive in nature and was not designed or suffi-
ciently powered to determine the statistical significance of safety
or PD/efficacy endpoints. The intent-to-treat (ITT) popula-
tion consisted of all patients who enrolled in the trial. The safety
population consisted of all patients in the ITT population who
received at least 1 dose of teduglutide or SOC. The ITT popu-
lation was analyzed for PD/efficacy endpoints except for analy-
sis of percentage change from baseline in EN volume and
calories (ie, analysis did not include patients who did not receive
EN at baseline [n = 10] or did not have EN volume/calorie data
recorded at baseline [n = 1], because it is mathematically im-
possible to calculate a percentage change when the baseline is
zero). Patients with no baseline EN intake were included in
calculations of actual change in EN volume and calories. Patient
electronic case report forms or diaries were used as sources for
data collection and management. All data were entered into
a preformatted database, verified, quality-checked, and sub-
mitted for statistical evaluation.
Adverse events (AEs) were coded with the Medical Diction-
ary for Regulatory Activities.18 TEAEs were summarized by
system organ class, preferred term, and treatment group by the
use of descriptive statistics. TESAEs were tabulated by overall
and treatment-related events. Missing safety variables were not
imputed. The absolute values and change from baseline in PD/
efficacy variables at each scheduled visit for each treatment
group were presented as median (min, max) and also sum-
marized by descriptive summary statistics.
Results
During the study period (November 2013-January 2015), 54
patients were screened and 42 patients were enrolled (Figure 1):
8 in the 0.0125 mg/kg/d cohort, 14 in the 0.025 mg/kg/d cohort,
15 in the 0.05 mg/kg/d cohort, and 5 in the SOC cohort. Forty
patients (95%) completed the study. One patient (0.05 mg/
kg/d) withdrew consent, and 1 patient (0.0125 mg/kg/d) was
removed from the study because of protocol noncompliance
(Figure 2; available at www.jpeds.com). Of the 42 enrolled pa-
tients, 32 were receiving formula-based liquid EN at baseline
(n = 4 in the SOC cohort and n = 28 in the combined teduglutide
cohorts). Baseline patient demographics are reported in Table II.
Indicators of clinical status remained stable throughout the
study period (Table III; available at www.jpeds.com). All pa-
tients experienced at least 1 TEAE. Most patients reported a
mild TEAE (95% and 100% of teduglutide- and SOC-treated
patients, respectively) or moderate TEAE (57% and 60%).
Severe TEAEs were reported by 30% of patients who re-
ceived teduglutide and by 20% of patients who received SOC.
The most common TEAE (Table IV) among all patients re-
ceiving teduglutide was vomiting, which was reported more
frequently in the 0.05 and 0.025 mg/kg/d cohorts (47% and
36%, respectively, compared with 0% in the 0.0125 mg/kg/d
and SOC cohorts). Other commonly reported TEAEs were
Active teduglutide treatment (12 weeks)
Screening 
≥2 weeks*
Screening 
≥2 weeks*
Screening 
≥2 weeks*
Screening 
≥2 weeks*
Active teduglutide treatment (12 weeks)
4-week
follow-up
4-week
follow-up
4-week
follow-up
4-week
follow-up
Lowest-dose cohort:
0.0125 mg/kg/d (n = 8)
Active teduglutide treatment (12 weeks)
Medium-dose cohort:
0.025 mg/kg/d (n = 14)
Highest-dose cohort:
0.05 mg/kg/d (n = 15)
Observation: standard of care (12 weeks, n = 5) 
Figure 1. Study design. *Safety data were assessed after ≥28 days of teduglutide treatment before the next dosing cohort could
proceed.
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Table II. Patient demographics at baseline
Variables SOC (n = 5)
Teduglutide, mg/kg/d
Total teduglutide (n = 37) Total (N = 42)Lowest dose 0.0125 (n = 8) Medium dose 0.025 (n = 14) Highest dose 0.05 (n = 15)
Age, y
Median (min, max) 2.0 (2, 3) 3.0 (1, 14) 4.0 (1, 14) 4.0 (1, 14) 4.0 (1, 14) 3.0 (1, 14)
1-3, n (%) 5 (100) 4 (50) 6 (43) 7 (47) 17 (46) 22 (52)
4-12, n (%) 0 3 (38) 7 (50) 7 (47) 17 (46) 17 (40)
13-17, n (%) 0 1 (13) 1 (7) 1 (7) 3 (8) 3 (7)
Sex, n (%)
Male 3 (60) 6 (75) 11 (79) 8 (53) 25 (68) 28 (67)
Female 2 (40) 2 (25) 3 (21) 7 (47) 12 (32) 14 (33)
Race, n (%)
White 3 (60) 6 (75) 11 (79) 13 (87) 30 (81) 33 (79)
Black 1 (20) 2 (25) 1 (7) 1 (7) 4 (11) 5 (12)
Asian 1 (20) 0 0 1 (7) 1 (3) 2 (5)
Other/not applicable 0 0 2 (14) 0 2 (5) 2 (5)
Reason for resection, n (%)*
Necrotizing enterocolitis 2 (40) 1 (13) 2 (14) 3 (20) 6 (16) 8 (19)
Midgut volvulus 2 (40) 2 (25) 4 (29) 7 (47) 13 (35) 15 (36)
Intestinal atresia 1 (20) 1 (13) 4 (29) 2 (13) 7 (19) 8 (19)
Gastroschisis 0 2 (25) 7 (50) 3 (20) 12 (32) 12 (29)
Other 0 2 (25) 0 1 (7) 3 (8) 3 (7)
Estimated residual small intestine length
n 5 7 13 13 33 38
Median (min, max), cm 35.0 (10, 75) 15.0 (2, 75) 68.0 (15, 145) 26.0 (0, 68) 30.0 (0, 145) 32.5 (0, 145)
Length of remaining anatomy determined by, n (%)
Surgery 4 (80) 5 (62.5) 7 (50) 12 (80) 24 (65) 28 (67)
Radiology 0 1 (12.5) 3 (21) 1 (7) 5 (13.5) 5 (12)
Other 1 (20) 2 (25) 4 (29) 2 (13) 8 (22) 9 (21)
Ileocecal valve present, n (%) 1 (20) 2 (25) 1 (7) 4 (27) 7 (19) 8 (19)
Intact colon, n (%) 5 (100) 7 (88) 14 (100) 14 (93) 35 (95) 40 (95)
Estimated colon remaining
n 5 6 11 12 29 34
Median (min, max), % 50 (33, 100) 85 (30, 100) 60 (10, 100) 78 (8, 100) 75 (8, 100) 75 (8, 100)
Colon-in-continuity, n (%)† 5 (100) 7 (100) 12 (86) 14 (100) 33 (94) 38 (95)
Undergone serial transverse enteroplasty procedure, n (%) 1 (20) 0 3 (21) 2 (13) 5 (14) 6 (14)
Fed EN via feeding tube, n (%)‡
Yes 4 (80) 4 (50) 12 (86) 9 (60) 25 (68) 29 (69)
No 0 0 1 (7) 2 (13) 3 (8) 3 (7)
Concomitant medications, n (%)
Antipropulsives 1 (20) 2 (25) 6 (43) 6 (40) 14 (38) 15 (36)
Probiotics§ 1 (20) 1 (13) 1 (7) 2 (13) 4 (11) 5 (12)
Bile acid preparations 0 1 (13) 0 2 (13) 3 (8) 3 (7)
Bile acid sequestrants 2 (40) 3 (38) 2 (21) 2 (13) 8 (22) 10 (24)
Proton pump inhibitors 1 (20) 1 (13) 7 (50) 7 (47) 15 (41) 16 (38)
H2 receptor antagonists 4 (80) 0 3 (21) 3 (20) 6 (16) 10 (24)
*Patients may have had ≥1 reason for resection. Each reason has been accounted for and thus sums may not total the n listed in the header and percentages may not total 100%.
†Percentages are based on patients with remaining colon in each treatment arm.
‡Category includes only those patients who received EN at baseline.
§Use of probiotics in this patient population is controversial; listing of probiotics as a concomitant medication is not intended as an endorsement of this practice.
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upper respiratory infection (27% teduglutide, 40% SOC),
catheter-related complication (24% teduglutide, 20% SOC),
and pyrexia (24% teduglutide, 40% SOC). The second most
common GI-related TEAE was abdominal pain (16%
teduglutide, 20% SOC). Overall, GI-related TEAEs occurred
in 67% (0.05 mg/kg/d), 71% (0.025 mg/kg/d), 50% (0.0125 mg/
kg/d), and 20% (SOC) of patients. AEs of special interest (ie,
intestinal obstruction; fluid overload; or gallbladder, biliary,
or pancreatic disease [colonic polyp formation not assessed]),
which were identified during the adult teduglutide clinical
program and reported in the teduglutide prescribing
information,17 were not evident during this smaller pediatric
study. There were no discontinuations due to TEAEs. Seven-
teen patients (46%) in the combined teduglutide cohorts ex-
perienced 34 TESAEs, and 3 patients (60%) in the SOC cohort
experienced 6 TESAEs (Table V; available at www.jpeds.com).
TESAEs reported in >2 patients treated with teduglutide were
pyrexia (n = 4 [11%] teduglutide; n = 2 [40%] SOC), central
line infection (n = 4 [11%] teduglutide; n = 0 SOC),and catheter-
related complication (n = 3 [8%] teduglutide; n = 1 [20%] SOC).
No deaths or TESAEs related to study drug occurred during
the study. No patient developed neutralizing antibodies to
teduglutide. One patient (0.025 mg/kg/d) tested positive for
non-neutralizing antiteduglutide antibodies at week 16. This
patient had no hypersensitivity or injection-site reactions, and
PN requirements remained stable during the study.At a 3-month
follow-up visit, the patient tested negative for antibodies.
Teduglutide treatment was associated with trends toward de-
creased PN volume and calorie requirements in the 0.025 and
0.05 mg/kg/d cohorts, which were observed as early as week
4 (Figure 3, A and B). At week 12, weekly prescribed PN volume
was changed by a median (min, max) of −2.3 (−6.9, 0) L/wk
and −1.3 (−11.0, 1.0) L/wk in the 0.025 and 0.05 mg/kg/d
cohorts, respectively. In contrast, median PN volume re-
mained near baseline in the 0.0125 mg/kg/d and SOC groups
(median change at week 12: 0 [−2.5, 0] L/wk and 0 [−0.3, 1.4]
L/wk, respectively). On the basis of patient diary data, the
median change in daily PN infusion time at 12 weeks was 0
(0, 2.0), −4.0 (−9.0, 2.0), and −3.0 (−12.0, 0.8) hours per day
in the 0.0125, 0.025, and 0.05 mg/kg/d cohorts, respectively;
change in PN infusion time was 0 (−2.0, 0.6) hours per day
in the SOC cohort. At week 12, PN calories changed by −1 (−5,
5), −2 (−12, 3), −17 (−39, 2), and −17 (−45, 53) kcal/kg/d in
the SOC, 0.0125, 0.025, and 0.05 mg/kg/d groups, respec-
tively. Four patients receiving teduglutide achieved indepen-
dence from PN: 3 of 15 in the 0.05 mg/kg/d cohort (achieved
at weeks 4, 8, and 12) and 1 of 14 in the 0.025 mg/kg/d cohort
(achieved at week 11) (Table VI; available at www.jpeds.com).
At week 16 (4 weeks after teduglutide discontinuation), 2 of
these 4 patients had resumed PN and 2 remained PN
independent.
On the basis of patient diary data from the ITT popula-
tion, including those patients who did not receive EN, the EN
volume changed by a median of +0.5 (0, 1.7) L/wk in the SOC
cohort, +1.1 (0, 12.5) L/wk in the 0.0125 mg/kg/d cohort, +2.3
(−0.9, 8.8) L/wk in the 0.025 mg/kg/d cohort, and +0.7 (0, 3.9)
L/wk in the 0.05 mg/kg/d cohort. At week 12, EN calorie intake
changed by a median of +2 (−3, 20), +9 (−18, 72), and +7 (−1,
63) kcal/kg/d in the 0.0125, 0.025, and 0.05 mg/kg/d groups,
respectively, and by +5 (0, 47) kcal/kg/d in the SOC group.
Table IV. TEAEs occurring in >5% of the pooled teduglutide dose cohorts
Preferred terms, n (%)* SOC (n = 5)
Teduglutide, mg/kg/d
Total teduglutide
(n = 37)
Lowest dose 0.0125
(n = 8)
Medium dose 0.025
(n = 14)
Highest dose 0.05
(n = 15)
Vomiting 0 0 5 (36) 7 (47) 12 (32)
Upper respiratory tract infection 2 (40) 2 (25) 4 (29) 4 (27) 10 (27)
Catheter-related complication 1 (20) 3 (38) 4 (29) 2 (13) 9 (24)
Pyrexia 2 (40) 0 2 (14) 7 (47) 9 (24)
Cough 1 (20) 1 (13) 2 (14) 4 (27) 7 (19)
Abdominal pain 1 (20) 1 (13) 1 (7) 4 (27) 6 (16)
Headache 0 1 (13) 2 (14) 2 (13) 5 (14)
Nausea 0 1 (13) 2 (14) 2 (13) 5 (14)
Fatigue 0 0 1 (7) 4 (27) 5 (14)
Blood bicarbonate decreased 2 (40) 1 (13) 1 (7) 3 (20) 5 (14)
Diarrhea 1 (20) 0 1 (7) 3 (20) 4 (11)
Fecal volume increased 0 1 (13) 1 (7) 2 (13) 4 (11)
Central line infection 0 0 3 (21) 1 (7) 4 (11)
Abdominal distension 0 1 (13) 1 (7) 1 (7) 3 (8)
Flatulence 0 2 (25) 1 (7) 0 3 (8)
Hematochezia 0 2 (25) 1 (7) 0 3 (8)
Injection-site hemorrhage 0 0 0 3 (20) 3 (8)
Viral gastroenteritis 1 (20) 1 (13) 0 2 (13) 3 (8)
Nasopharyngitis 0 2 (25) 0 1 (7) 3 (8)
Weight decreased 0 1 (13) 1 (7) 1 (7) 3 (8)
Dizziness 0 0 1 (7) 2 (13) 3 (8)
Rash 0 0 1 (7) 2 (13) 3 (8)
GI stoma complication† 0 0 0 1 (100) 1 (25)
*Percentages are based on the number of patients in each treatment group.
†Percentages are based on the number of patients with a stoma in each treatment group.
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Changes in EN volume and calories from baseline are re-
ported in Figure 3, C and D.
Overall, trends suggestive of PN reductions and EN im-
provements over baseline values persisted during the first 4
weeks of treatment (Figure 3). Point estimates of median
change in PN weekly volume requirements were increased at
week 16 (ie, 4 weeks after teduglutide discontinuation) com-
pared with week 12 (ie, at end of treatment) but remained lower
than baseline values in the 2 highest teduglutide dose cohorts:
−2.2 (−6.9, 0.3) L/wk for the 0.025 mg/kg/d cohort and −0.9
(−9.0, 1.9) L/wk for the 0.05 mg/kg/d cohort. In contrast, point
estimates for median change in PN volume at week 16 were
closer to baseline values in the 0.0125 mg/kg/d and SOC
cohorts: −0.2 (−2.5, 0) and 0.0 (−0.9, 1.4) L/wk, respectively.
A similar pattern was observed for prescribed PN calories. At
week 16, PN calories were changed by −1 (−10, 1), −9 (−39,
8), and −15 (−40, 6) kcal/kg/d from baseline in the 0.0125, 0.025,
and 0.05 mg/kg/d cohorts, respectively. In the SOC cohort at
week 16, prescribed PN calories were near baseline (median
change, 0 [−13, 1] kcal/kg/d). After 4 weeks off teduglutide,
point estimates of EN volume and calories were maintained
or increased compared with baseline. Median EN volume
changed by +0.9 (0, 1.7), +3.2 (0, 10.5), +3.5 (−1.9, 8.7), and
+0.8 (0, 3.5) L/wk vs baseline in the SOC, 0.0125, 0.025, and
0.05 mg/kg/d cohorts, respectively. Prescribed EN calories
changed by +6 (0, 48) kcal/kg/d vs baseline with SOC, by +5
(−5, 27) kcal/kg/d with 0.0125 mg/kg/d, by +11 (−20, 72) kcal/
kg/d with 0.025 mg/kg/d, and by +2 (−3, 64) kcal/kg/d with
0.05 mg/kg/d teduglutide.
Median plasma citrulline levels at baseline, week 12, and week
16 (4 weeks after teduglutide discontinuation) are reported in
Table VII (available at www.jpeds.com). Broad variability in
baseline citrulline values was observed, but median change from
baseline in citrulline levels increased in all teduglutide cohorts
at week 12.
Discussion
Population pharmacokinetic modeling and simulation data in-
dicated that pediatric patients >1 year of age would likely require
the same teduglutide dosage approved for adult patients (ie,
0.05 mg/kg/d).17 Preliminary modeling also suggested that lower
doses may show some benefit in children. Therefore, a con-
servative approach was taken, and 2 lower doses were inves-
tigated first.
Teduglutide had a generally good safety profile and was well
tolerated by pediatric patients at the doses tested. GI events
were reported at a relatively low frequency overall, but most
were more common in the 0.025 mg/kg/d and 0.05 mg/kg/d
teduglutide dose cohorts than in the SOC cohort (Table IV).
Despite GI events, most patients treated with teduglutide com-
pleted the study. The overall safety profile was consistent with
the adult SBS population. The most commonly reported TEAEs
in the teduglutide-treated population were GI-related AEs,
upper respiratory tract infection, catheter-related complica-
tions, and pyrexia, all of which were observed in the short-
term studies of teduglutide in adult patients.19,20 The study
protocol included frequent study visits because of the poten-
tial for treatment-associated AEs identified in the adult clini-
cal trial program and reported as AEs of special interest in the
teduglutide US prescribing information.17 None of these AEs
were observed.
Teduglutide treatment was associated with trends toward de-
creases in PN requirements and increases in EN intake in a
study population that had not experienced any clinically mean-
ingful reductions in PN and minimal or no advance in EN
feedings for ≥3 months. Trends suggestive of improvements
in EN feedings also were observed in the SOC cohort during
this study, in terms of a median 11% increase in EN volume
and a 41% increase in EN kcal/kg/d at week 12 vs baseline. Pa-
tients receiving SOC in this study likely benefited from inten-
sive, high-frequency patient management at experienced
intestinal rehabilitation centers, which are associated with im-
proved outcomes in patients with pediatric SBS.21 The SOC
cohort also was a younger population (2 vs 4 years of age in
the pooled teduglutide cohorts) and, therefore, perhaps more
capable of endogenous intestinal adaptation.
Citrulline levels also were assessed during this study, but the
results were clouded by wide variability of baseline values. In
the 0.05 mg/kg/d teduglutide cohort, point estimates showed
a median increase in the change of plasma citrulline between
baseline and week 12, but the absolute median values for plasma
citrulline levels virtually were unchanged. In adults with SBS-
IF, treatment with teduglutide has been associated with sig-
nificant (P < .0001 vs placebo) increases in plasma citrulline.22
Additional studies with larger sample sizes will need to be con-
ducted to determine whether the same correlation is noted in
pediatric patients or to determine whether children need longer
courses or greater doses of teduglutide than adults to achieve
a consistent effect on plasma citrulline.
Although not directly comparable, the PN decreases (−41%
and −25% in the 0.025 and 0.05 mg/kg/d cohorts, respec-
tively) were in range with reductions observed in adults re-
ceiving teduglutide 0.05 mg/kg/d in the pivotal phase 3 clinical
trial (−32%).20 In the current study, 4 patients were weaned
successfully from PN with teduglutide after up to 12 years of
PN dependence. PN had to be resumed in 2 of these patients
at week 16 (4 weeks after teduglutide discontinuation), sug-
gestive of a treatment-related improvement while on treat-
ment. Considering the safety profile observed in this study at
all doses and trends suggesting decreased PN requirements and
EN advancements at the 2 greater teduglutide doses, the benefit/
risk profile for teduglutide was more favorable with 0.025 and
0.05 mg/kg/d teduglutide. Patients in the 0.025 and 0.05 mg/
kg/d cohorts reduced PN volume (L/wk) by 25% to 41% and
PN calories (kcal/kg/d) by 45% to 52% while increasing EN
volume by 32% to 40% and EN calories by 26% to 63%. In
addition, 4 of 29 patients in these 2 cohorts achieved PN in-
dependence during the treatment period. Nonetheless, these
results are tempered by the recognized limitations of this short-
term, open-label study. The treatment period of this study was
only 12 weeks; in adult patients with SBS-IF, teduglutide ad-
ministered over 30 months yielded continued PN reductions
throughout extended treatment.23 The relatively short study
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Figure 3. Median percentage change from baseline in prescribed weekly A, PN volume and B, PN calories and median percent-
age change from baseline in C, weekly EN volume per patient diary data and D, prescribed EN calories during 12 weeks of teduglutide
administration and for 4 weeks after treatment discontinuation (weeks 13-16). Analyses of percentage change in EN volume and
calories did not include patients who did not receive EN at baseline (n = 11). Error bars represent min, max values. (Continues)
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Figure 3. Continued.
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period did not allow us to evaluate the effects of teduglutide
on long-term outcomes such as growth.
Furthermore, analyses of EN calorie and volume data were
based on liquid nutrition only and did not encompass other
ad lib enteral consumption. If teduglutide, as anticipated, en-
hanced ad lib intake and subsequent nutritional absorption,
then the assessments of EN volume and calories may have un-
derestimated the potential beneficial impact of teduglutide. In
addition, the analyses of actual change in EN calorie and volume
data during the study were calculated for the ITT population
and thus included those patients who did not receive EN. Re-
ported changes in PN infusion time at week 12 could repre-
sent either adjustments in PN volume or modifications of the
infusion schedule (ie, cycling), but the accompanying PN
volume time course data support trends for reduced PN volume
with greater doses of teduglutide. The pool of eligible pa-
tients for this study was small, and, as such, the sample size
was based on the available patient population rather than on
a statistical power calculation. More patients were assigned to
the 2 greater-dose cohorts, which were hypothesized to be more
likely to elicit clinically relevant effects, than to the 0.0125 mg/
kg/d and SOC cohorts. Moreover, recruitment into the SOC
cohort in this open-label study was hindered by lack of inter-
est or perceived benefit among patients and guardians, and this
cohort included no patients older than 3 years of age. Thus,
the study was not powered sufficiently to determine the sta-
tistical significance of safety or PD/efficacy endpoints, and only
descriptive statistics were used. Finally, 3 study centers en-
rolled ≥5 patients (n = 5, 6, and 7, respectively), leading to the
possibility of a “center effect,” in which the specific practice
patterns of those centers may have exerted a disproportion-
ate influence on study results. Many of the aforementioned limi-
tations can be attributed to the fact that pediatric SBS is an
orphan condition, making impossible the stratification of the
small number of patients enrolled by age, diagnosis, bowel
length, or baseline intestinal function.
Effects of teduglutide treatment persisted for at least 4 weeks
following drug discontinuation. Although point estimates for
PN volume increased at 4 weeks after teduglutide discontinu-
ation compared with end of treatment, median PN volumes
remained lower than baseline levels in the 2 greater-dose cohorts
(0.025 and 0.05 mg/kg/d). Similarly, compared with end of
treatment, trends suggesting advancements in EN feeds were
maintained during the 4 weeks after teduglutide discontinu-
ation. Of the 4 patients who achieved enteral autonomy with
teduglutide treatment, 2 maintained PN independence at the
4-week follow-up. Study data were not collected past week 16.
In this initial, 3-month, open-label study, teduglutide treat-
ment was associated with trends toward reductions in PN needs
and advancements in EN in children with SBS-IF, particu-
larly at the greater doses tested, 0.025 and 0.05 mg/kg/d.
Teduglutide had a favorable safety profile and was well toler-
ated across all dosing cohorts. A 24-week study that com-
pared the safety and efficacy of 0.025 and 0.05 mg/kg/d
teduglutide vs SOC treatment in pediatric patients with SBS-
IF (ClinicalTrials.gov, NCT02682381) will yield additional data
regarding optimal teduglutide dosing. ■
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50 Years Ago in The Journal of Pediatrics
Cerebral Lesions in Congenital Rubella Syndrome
Rorke LB, Spiro AJ. J Pediatr 1967;70:243-55
Before the release of the rubella vaccine in 1969, more than 20 000 infants in the US were born with congenitalrubella syndrome.1 Affected infants had neurosensory deficits including microcephaly, intellectual disabilities, cata-
racts, glaucoma, and hearing loss. As with the Zika virus today, there was controversy and a bit of mystery regarding
how the virus affected the central nervous system in utero. In 1967, before the availability of advanced neuroimaging,
pathologists were the specialists who evaluated brain development and injury.
Fifty years ago in The Journal, pediatric neuropathologists Rorke and Spiro reported a case series of 9 infants who
died before age 1 year with confirmed or presumed congenital rubella. The brains of the infants exhibited widespread
vascular injury with resulting ischemic lesions in watershed areas, including the periventricular white matter, but no
structural malformations of the brain or inflammation were evident. Older infants had poor myelination. The pedi-
atric neuropathologists had rarely seen this constellation of findings. They also found vascular injury to the pulmo-
nary, renal, hepatic, and pancreatic vessels, and speculated that vascular degeneration and resulting ischemia was the
primary cause of brain injury with fetal rubella infection. This report was one of many that established the sensori-
neural consequences of congenital infection with rubella and provided the impetus for public health campaigns that
have eliminated endemic rubella in the US.1
Today, the Zika virus presents a new threat to the fetus. As with congenital rubella, when Zika virus infection first
emerged as a threat, there was controversy about whether and how it caused brain injury in the fetus. Our current
research toolkit is enhanced by the availability of fetal neuroimaging and identification of the viral genome in brain
tissue,2 but now, as in 1967, careful neuropathologic evaluation of suspected cases continues to be important in es-
tablishing disease pathogenesis.
Raye-Ann deRegnier, MD
Department of Pediatrics
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois
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Assessed for
eligibility
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Figure 2. Patient disposition.
Table I. Guidance for PN and nutritional support
adjustments
Types of
adjustment Measurement Action taken
Fluid Intake exceeds output by
>400 mL/m2
PN volume decreased and
oral/enteral volume
increased
Intake exceeds output by
0-400 mL/m2
No action taken
Intake less than output by
>400 mL/m2
PN volume increased; oral/
enteral volume not
changed
Calorie Weight loss >5% of body
weight
PN calories increased
Weight increased beyond
expected weight gain*
between 2 study visits
PN calories decreased and
oral/enteral calories
increased
Weight change <5% of
body weight
No change to PN calories;
oral/enteral calories
increased
*Expected weight gain: > 5-10 g/d for toddlers aged 1-2 y and >3-5 g/d for children
aged >2 y.
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Table III. Clinical status
Variables SOC (n = 5)
Teduglutide, mg/kg/d
Lowest dose 0.0125 (n = 8) Medium dose 0.025 (n = 14) Highest dose 0.05 (n = 15)
Height, cm
Baseline
n 5 8 14 15
Median (min, max) 92.0 (82.0, 95.0) 95.2 (80.0, 160.3) 100.4 (80.6, 158.8) 99.6 (76.1, 145.5)
Week 12
n 5 7 12 13
Median (min, max) 91.7 (84.7, 94.2) 103.0 (84.0, 161.5) 104.5 (81.2, 161.0) 99.5 (87.1, 147.9)
Change
n 5 7 12 13
Median (min, max) 2.1 (−3.3, 2.7) 1.2 (−0.2, 4.0) 1.9 (−0.6, 6.7) 1.7 (0.1, 11.0)
Weight, kg
Baseline
n 5 8 14 15
Median (min, max) 12.3 (11.2, 14.8) 13.3 (10.1, 48.7) 17.4 (10.3, 44.3) 16.1 (10.5, 38.5)
Week 12
n 5 7 12 13
Median (min, max) 13.1 (11.7, 15.7) 16.0 (11.2, 50.4) 17.2 (10.2, 53.4) 16.1 (10.8, 35.8)
Change
n 5 7 12 13
Median (min, max) 0.5 (0.1, 0.9) 0.8 (0.3, 2.1) 0.4 (−0.7, 9.1) 0.3 (−2.7, 2.0)
Weight, z score
Baseline
n 5 7 9 14
Median (min, max) −0.5 (−1.6, 0.5) −1.2 (−1.6, 0.1) −0.3 (−0.9, 2.4) −0.2 (−1.7, 1.2)
Week 12
n 5 7 10 12
Median (min, max) −0.5 (−1.2, 1.3) −0.2 (−0.9, 0.3) 0.04 (−1.0, 2.8) −0.5 (−3.0, 1.5)
Change
n 5 7 8 12
Median (min, max) 0.4 (0, 1.2) 0.3 (−0.1, 1.2) 0.3 (−1.7, 2.1) −0.03 (−3.1, 1.3)
Serum electrolytes
Calcium, mmol/L
Baseline
n 5 8 14 15
Median (min, max) 2.4 (2.2, 2.5) 2.4 (2.0, 2.7) 2.4 (2.2, 2.6) 2.3 (2.3, 2.5)
Week 12
n 5 7 13 13
Median (min, max) 2.3 (2.1, 2.4) 2.3 (2.1, 2.5) 2.3 (2.2, 2.5) 2.3 (2.1, 2.5)
Change
n 5 7 13 13
Median (min, max) −0.1 (−0.3, 0.1) −0.1 (−0.1, 0.4) −0.1 (−0.2, 0.0) 0.0 (−0.3, 0.2)
Phosphate, mmol/L
Baseline
n 5 8 14 15
Median (min, max) 1.6 (1.6, 1.8) 1.7 (1.3, 1.8) 1.5 (1.1, 1.9) 1.6 (1.2, 1.9)
Week 12
n 5 7 13 13
Median (min, max) 1.7 (1.5, 1.7) 1.6 (1.1, 1.7) 1.6 (0.9, 1.9) 1.6 (0.9, 1.9)
Change
n 5 7 13 13
Median (min, max) −0.1 (−0.2, 0.1) −0.1 (−0.2, 0.0) −0.1 (−0.6, 0.6) 0.0 (−0.6, 0.3)
Magnesium, mmol/L
Baseline
n 5 8 14 15
Median (min, max) 0.8 (0.8, 0.8) 0.8 (0.6, 0.9) 0.8 (0.7, 1.0) 0.8 (0.7, 0.9)
Week 12
n 5 7 13 13
Median (min, max) 0.8 (0.7, 0.8) 0.8 (0.8, 0.9) 0.8 (0.6, 0.9) 0.8 (0.5, 0.9)
Change
n 5 7 13 13
Median (min, max) 0.0 (−0.1, 0.0) 0.0 (−0.1, 0.2) 0.0 (−0.4, 0.1) 0.0 (−0.2, 0.1)
Liver function tests and liver enzymes
Albumin, g/L
Baseline
n 5 8 14 15
Median (min, max) 39.0 (36, 40) 39.0 (37, 44) 38.5 (31, 44) 39.0 (35, 46)
Week 12
(continued)
February 2017 ORIGINAL ARTICLES
111.e2Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome
Table III. Continued
SOC (n = 5)
Teduglutide, mg/kg/d
Lowest dose 0.0125 (n = 8) Medium dose 0.025 (n = 14) Highest dose 0.05 (n = 15)
n 5 7 13 13
Median (min, max) 36.0 (32, 40) 39.0 (33, 44) 38.0 (33, 43) 38.0 (27, 44)
Change
n 5 7 13 13
Median (min, max) −3.0 (−4, 2) −1.0 (−6, 3) −1.0 (−9, 4) −2.0 (−12, 3)
Alkaline phosphatase, U/L
Baseline
n 5 8 14 15
Median (min, max) 221.0 (167, 649) 338.0 (181, 423) 227.0 (120, 396) 288.0 (120, 482)
Week 12
n 5 7 13 13
Median (min, max) 186.0 (119, 424) 296.0 (172, 388) 203.0 (89, 247) 248.0 (84, 482)
Change
n 5 7 13 13
Median (min, max) −44.0 (−225, −12) −15.0 (−131, 32) −9.0 (−120, 66) −51.0 (−135, 194)
Alanine aminotransferase, U/L
Baseline
n 5 8 14 15
Median (min, max) 25.0 (21, 51) 71.0 (19, 140) 35.0 (11, 179) 50.0 (24, 136)
Week 12
n 5 7 13 13
Median (min, max) 35.0 (21, 40) 58.0 (24, 142) 30.0 (11, 77) 46.0 (23, 98)
Change
n 5 7 13 13
Median (min, max) 0.0 (−11, 13) −8.0 (−82, 44) −3.0 (−102, 19) −3.0 (−91, 34)
Aspartate aminotransferase
Baseline
n 5 8 14 15
Median (min, max) 36.0 (35, 76) 54.5 (20, 72) 39.0 (16, 85) 43.0 (22, 69)
Week 12
n 5 7 13 13
Median (min, max) 46.0 (30, 64) 49.0 (30, 161) 37.0 (20, 75) 39.0 (29, 116)
Change
n 5 7 13 13
Median (min, max) −2.0 (−20, 21) −1.0 (−15, 89) 5.0 (−27, 22) −6.0 (−22, 47)
Bilirubin, mmol/L
Baseline
n 5 8 14 15
Median (min, max) 2.0 (2, 7) 3.0 (2, 10) 3.0 (2, 9) 3.0 (2, 19)
Week 12
n 5 7 13 13
Median (min, max) 2.0 (2, 15) 3.0 (2, 14) 3.0 (2, 9) 3.0 (2, 11)
Change
n 5 7 13 13
Median (min, max) 0.0 (−2, 10) 0.0 (−3, 4) 0.0 (−1, 5) 0.0 (−8, 5)
Blood urea nitrogen, mmol/L
Baseline
n 5 8 14 15
Median (min, max) 4.0 (3, 6) 5.0 (1, 8) 5.2 (3, 8) 4.70 (3, 8)
Week 12
n 5 7 13 13
Median (min, max) 3.7 (2, 7) 4.4 (3, 7) 4.9 (3, 6) 4.5 (3, 6)
Change
n 5 7 13 13
Median (min, max) −0.6 (−1, 2) −0.3 (−3, 1) −1.4 (−3, 2) −0.4 (−1, 2)
Gamma glutamyl transferase, U/L
Baseline
n 5 8 14 15
Median (min, max) 23.0 (10, 99) 33.5 (8, 112) 18.0 (10, 82) 21.0 (10, 78)
Week 12
n 5 7 13 13
Median (min, max) 16.0 (11, 93) 14.0 (5, 115) 13.0 (5, 35) 27.0 (8, 108)
Change
n 5 7 13 13
Median (min, max) −6.0 (−7, 2) −2.0 (−54, 49) −5.0 (−47, 14) 6.0 (−30, 70)
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Table III. Continued
SOC (n = 5)
Teduglutide, mg/kg/d
Lowest dose 0.0125 (n = 8) Medium dose 0.025 (n = 14) Highest dose 0.05 (n = 15)
Kidney function tests and pancreatic enzymes
Creatinine, mmol/L
Baseline
n 5 8 14 15
Median (min, max) 28.0 (23, 31) 34.0 (16, 57) 29.5 (19, 53) 27.0 (19, 43)
Week 12
n 5 7 13 13
Median (min, max) 26.0 (21, 27) 35.0 (16, 61) 27.0 (19, 51) 27.0 (19, 78)
Change
n 5 7 13 13
Median (min, max) −4.0 (−5, 3) 0.0 (−8, 5) −1.0 (−10, 11) 4.0 (−4, 55)
Amylase, U/L
Baseline
n 5 8 14 15
Median (min, max) 41.0 (21, 45) 54.0 (20, 83) 57.0 (21, 178) 48.0 (40, 115)
Week 12
n 5 7 13 13
Median (min, max) 37.0 (25, 41) 53.0 (21, 75) 52.0 (25, 226) 58.0 (40, 73)
Change
n 5 7 13 13
Median (min, max) 0.0 (−8, 4) 1.0 (−17, 5) 4.0 (−23, 48) 3.0 (−42, 15)
Triacylglycerol lipase, U/L
Baseline
n 5 8 14 15
Median (min, max) 29.0 (14, 42) 29.0 (14, 135) 23.5 (13, 66) 19.0 (13, 48)
Week 12
n 5 7 13 13
Median (min, max) 21.0 (15, 71) 21.0 (16, 49) 21.0 (10, 51) 19.0 (10, 31)
Change
n 5 7 13 13
Median (min, max) 0.0 (−14, 29) −2.0 (−15, 7) 1.0 (−20, 14) 0.0 (−23, 13)
Table V. Summary of TESAEs
Preferred terms, n (%)* SOC (n = 5)
Teduglutide, mg/kg/d
Total teduglutide
(n = 37)
Lowest dose
0.0125 (n = 8)
Medium dose
0.025 (n = 14)
Highest dose
0.05 (n = 15)
Pyrexia 2 (40) 0 1 (7) 3 (20) 4 (11)
Central line infection 0 0 3 (21) 1 (7) 4 (11)
Catheter-related complication 1 (20) 0 2 (14) 1 (7) 3 (8)
Parainfluenza virus infection 0 0 1 (7) 1 (7) 2 (5)
Pancytopenia 0 0 0 1 (7) 1 (3)
Abdominal distension 0 0 1 (7) 0 1 (3)
Frequent bowel movements 0 0 0 1 (7) 1 (3)
Hematochezia 0 0 1 (7) 0 1 (3)
Fatigue 0 0 0 1 (7) 1 (3)
Irritability 0 0 0 1 (7) 1 (3)
Anaphylactic reaction 0 0 0 1 (7) 1 (3)
Adenovirus infection 0 1 (13) 0 0 1 (3)
Catheter-related infection 0 1 (13) 0 0 1 (3)
Catheter sepsis 0 0 0 1 (7) 1 (3)
Influenza 0 1 (13) 0 0 1 (3)
Rhinovirus infection 0 0 1 (7) 0 1 (3)
Blood creatinine increased 0 0 1 (7) 0 1 (3)
Dehydration 0 0 0 1 (7) 1 (3)
Depressed level of consciousness 0 0 0 1 (7) 1 (3)
Grand mal convulsion 0 0 1 (7) 0 1 (3)
Rash 0 0 1 (7) 0 1 (3)
Hypovolemic shock 0 0 1 (7) 0 1 (3)
Fungemia 1 (20) 0 0 0 0
Viral gastroenteritis 1 (20) 0 0 0 0
Viral infection 1 (20) 0 0 0 0
*Percentages are based on the number of patients in each treatment group; a single patient may have reported ≥1 TESAE.
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Table VI. Characteristics of patients weaned from PN/intravenous fluids
Variables Patient 1 Patient 2 Patient 3 Patient 4
Cohort, teduglutide mg/kg/d Medium dose, 0.025 Highest dose, 0.05 Highest dose, 0.05 Highest dose, 0.05
Age, y 14 8 6 14
Sex Male Female Male Male
Etiology Gastroschisis Intestinal atresia Hirschsprung disease Midgut volvulus
Remaining small bowel length, cm 145 23 51 0
Stoma present (stoma type, if applicable) No No Yes (ileostomy) No
Colon remaining, % 100 100 0 100
Time since last surgical resection, y 1.0 8.4 4.3 12.2
Remaining anatomy determined by Surgery or operative
report/parental history
Surgery or operative
report
Surgery or operative
report
Surgery or operative
report
GI symptoms
Abnormal or irregular bowel movements Moderate None None None
Diarrhea, loose Moderate Mild Severe None
Gas, bloating Mild None None None
Heartburn, reflux, spit up None None None Mild
Nausea, feeling queasy Moderate None None None
Vomiting Moderate None None None
Teduglutide exposure at weaning, wk 10.7 4.1 12.1 8.1
Time on PN at baseline, y 1.3 8.3 6.7 12.2
Prescribed PN volume at screening, L/wk 6.9 4 9.5 11
Prescribed PN calorie at screening, kcal/wk 6747 3788 6701 4767
Prescribed number of days per week of PN at screening 7 4 7 5
Time on EN at baseline, y 14.3 N/A N/A N/A
Prescribed EN volume at screening, L/wk 10.1 N/A N/A N/A
Prescribed EN calorie at screening, kcal/wk 6720 N/A N/A N/A
Hours per day feeding tube used 24 N/A N/A N/A
Change in actual EN volume at week 12, L/wk (%) 8.4 (82.9) N/A N/A N/A
Resumed PN after teduglutide discontinuation No No Yes Yes
N/A, not applicable (ie, patient did not receive EN).
Table VII. Plasma citrulline levels during and after teduglutide treatment
Variables
Teduglutide, mg/kg/d
0.0125 0.025 0.05
(n = 8) (n = 14) (n = 15)
Median (min, max)
Baseline, mmol/L 14.7 16.1 16.8*
(3.8, 25.3) (6.4, 29.8) (4.5, 30.6)
Week 12, mmol/L 18.6† 22.0‡ 16.7*
(6.2, 48.2) (7.8, 47.0) (4.2, 72.9)
Change from baseline at week 12, mmol/L 1.0† 5.4‡ 7.5‡
(−0.8, 22.9) (1.1, 17.2) (−13.9, 56.5)
Change from baseline at week 12, % 12† 34‡ 78‡
(−4, 91) (10, 91) (−51, 345)
Week 16 (4 weeks after end of study drug treatment), mmol/L 15.1† 17.5 9.5*
(6.5, 50.6) (6.8, 35.8) (2.9, 48.2)
Change from baseline at week 16, mmol/L 1.0† 1.9 0.4‡
(−4.2, 25.3) (−2.4, 6.8) (−19.1, 28.2)
Change from baseline at week 16, % 8† 12 5‡
(−30, 100) (−21, 50) (−67, 172)
*n = 14.
†n = 7.
‡n = 13.
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